Clinical Data Lilly’s ‘triple G’ retatrutide aces crucial obesity trial PharmaphorumLilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum Lilly’s retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rollingNext: Lilly’s triple agonist shows bariatric surgery-like weight loss results Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
